Autolus Therapeutics plc (AUTL)

Develops next-generation programmed T cell therapies for the treatment of cancer.

AUTL Stock Quote

Company Report

Autolus Therapeutics plc, headquartered in London, United Kingdom, is a dynamic clinical-stage biopharmaceutical company dedicated to advancing innovative T cell therapies for the treatment of cancer. The company's robust pipeline includes several promising programs aimed at harnessing the power of programmed T cells to target various cancers effectively.

Among its clinical-stage programs, Autolus Therapeutics is advancing obecabtagene autoleucel (AUTO1), a CD19-targeting T cell therapy currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in Phase 1 trials for pediatric patients with relapsed or refractory ALL. The company's portfolio also features AUTO4, designed for peripheral T-cell lymphoma, AUTO6NG targeting GD2 for neuroblastoma in preclinical trials, and AUTO8 undergoing Phase I trials for multiple myeloma. Autolus Therapeutics is also actively developing AUTO5, a hematological product candidate in preclinical stages.

Founded in 2014, Autolus Therapeutics has rapidly emerged as a leader in the field of T cell therapies, leveraging cutting-edge research and strategic collaborations to advance its pipeline. With a steadfast commitment to transforming cancer treatment paradigms, the company continues to pioneer novel therapies that hold promise for improving outcomes and quality of life for patients worldwide.

AUTL EPS Chart

AUTL Revenue Chart

Stock Research

INHD VGR TXMD CIFR MLNK TTD HOFV

AUTL Chart

View interactive chart for AUTL

AUTL Profile

AUTL News

Analyst Ratings